A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
← catalyst calendarNCT05081557 · readout ≤ 73 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
873actual
Sites
140
Countries
Argentina, Australia, Austria +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-17 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Primary outcomes
what the primary-completion date above is the date OFUpadacitinib (UPA) Utilization Patterns
measured Up to Approximately 24 Months
Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) 0/1
measured Month 4
vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD 0/1 at Month 4
measured Month 24
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed